NCT02154360View on ClinicalTrials.gov

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

June 30, 2016

Conditions
HIV Infection
Interventions
DRUG

Aprepitant

Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days

Trial Locations (1)

19104

Hospital of the University of Pennsylvania Clinical Research Site, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT02154360 - Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects | Biotech Hunter | Biotech Hunter